1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Endymed Ltd

Endymed Ltd

ENDY.TA
Endymed LtdIL flagTel Aviv Stock Exchange
320.10
ILA
- -
- -
44.05MMarket Cap
Endymed Ltd
ENDY.TA
(Tel Aviv Stock Exchange)

Recent

price

320.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
FRC
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
9
9
11
14
14
14
14
14
Basic Weighted Avg Shares
14
18
18
16
14
22
21
23
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
1
1
- -
Depreciation Expense
-3
-3
2
2
- -
5
1
1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
1
1
1
1
1
LT Debt
- -
1
6
8
8
14
15
15
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
20.9%
3.87%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
272.31%
-34.94%
Sales/Revenue/Turnover
- -
6.58%
6.77%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available
Similar Companies
BICO Group AB (publ) (CLLKF)
Bonesupport Holding AB (publ) (0RQO.L)
Radiant Innovation Inc. (3373.TWO)
Rhinomed Limited (RHNMF)
Visioneering Technologies, Inc. (VTI.AX)
Ambu A/S (AMBFF)
Business
Endymed Ltd designs, develops, and commercializes energy-based medical aesthetic treatment systems for professional and consumer markets worldwide, including North America, Europe, the Middle East, Africa, Asia, Oceania, and Latin America; its core products encompass the ENDYMED PRO and the advanced ENDYMED PRO MAX, all-in-one RF platforms delivering up to 100W for skin tightening, wrinkle reduction, and body contouring; ENDYMED PURE 2.0 and Pure Laser, compact systems for flexible aesthetic procedures and laser hair removal; Intensif, an FDA-cleared non-insulated motorized RF microneedle technology; FSR for fractional skin resurfacing; Focused RF with 3DEEP handpieces for face, neck, and body treatments; NEWA, a home-use device for facial tightening and lifting; and ENDYMED Contour for cellulite reduction, addressing acne scars, stretch marks, and rejuvenation across all skin types. Founded in 2004 and headquartered in Caesarea, Israel, the company operates in the medical devices sector with approximately 46 employees, targeting clinics, med spas, and individual consumers through its proprietary FDA-cleared 3DEEP radiofrequency technology. In February 2025, Endymed completed a going-private transaction, acquired by Shanghai Haohai Biological Technology Co., Ltd., enhancing the buyer's medical aesthetics portfolio with Endymed's RF systems and marking the first such Chinese-led deal for a Tel Aviv Stock Exchange-listed firm since 2011.